伟德国际网址1946

伟德国际网址1946
Lifetech held the world premier for the clinical application of the Absnow™ Biodegradable ASD Closure System

Guangzhou, China – On October 23rd, the first global press release of the Lifetech Absnow™ biodegradable Atrial Septal Defect closure system was held at the Guangdong Cardiovascular Institute, Guangdong General Hospital, gathering representatives from multiple media around China. Professor Zhiwei Zhang, the deputy director of the Guangdong Cardiovascular Institute and chief physician of the Pediatric Cardiovascular Department, Guangdong General Hospital introduced and demonstrated the clinical application of this new device. Dr. Deyuan Zhang, the president and CTO of Lifetech Scientific co-hosted the conference.

 

The press conference started with an intervention demonstration of the Absnow™ ASD closure system from professor Zhang’s team. Within 30 minutes, the Absnow™ ASD closure system was successfully implanted for a 55 years old patient who suffered from atrial septal defect.

伟德国际网址1946

(Professor Zhiwei Zhang and his team at the case demonstration)


After the case demonstration, professor Zhang shared the feature of the Absnow™ ASD closure system as well as the progress of its clinical trial programs. So far, the Absnow™ biodegradable ASD closure system has been implanted in 14 patients around the world. The 3-months and 1-months follow up has been completed for 6 and 5 patients, respectively. Currently, the Absnow™ ASD closure system is planned for clinical trials in multiple centers in China, and more and more patients with ASDs will benefit from this innovative device.

伟德国际网址1946

(Professor Zhiwei Zhang (middle), Professor Yumei Xie (left) and Dr. Deyuan Zhang (right) introducing Absnow™ at the press conference)


About the Absnow™ Biodegradable Atrial Septal Defect Closure System – The Absnow™ ASD closure system is Lifetech Scientific’s new approach in coping with congenital heart diseases. The whole device is built in one single material – Poly-L-lactic Acid (PLLA). Unlike other nitinol-based CHD occluders, Absnow™ will not remain inside the patient’s body for rest of his/her life after the treatment is done. Instead, it will be absorbed and degraded by the human body.